Metformin, Cognitive Function, and Changes in the Gut Microbiome

Overview

Journal Endocr Rev

Publisher Oxford University Press

Specialty Endocrinology

Date 2023 Aug 21

PMID 37603460

Authors

Marisel Rosell-Diaz

Jose Manuel Fernandez-Real

Affiliations

Soon will be listed here.

Abstract

The decline in cognitive function and the prevalence of neurodegenerative disorders are among the most serious threats to health in old age. The prevalence of dementia has reached 50 million people worldwide and has become a major public health problem. The causes of age-related cognitive impairment are multiple, complex, and difficult to determine. However, type 2 diabetes (T2D) is linked to an enhanced risk of cognitive impairment and dementia. Human studies have shown that patients with T2D exhibit dysbiosis of the gut microbiota. This dysbiosis may contribute to the development of insulin resistance and increased plasma lipopolysaccharide concentrations. Metformin medication mimics some of the benefits of calorie restriction and physical activity, such as greater insulin sensitivity and decreased cholesterol levels, and hence may also have a positive impact on aging in humans. According to recent human investigations, metformin might partially restore gut dysbiosis related to T2D. Likewise, some studies showed that metformin reduced the risk of dementia and improved cognition, although not all studies are concordant. Therefore, this review focused on those human studies describing the effects of metformin on the gut microbiome (specifically the changes in taxonomy, function, and circulating metabolomics), the changes in cognitive function, and their possible bidirectional implications.

Citing Articles

The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications.

Zhang T, Zhou L, Makarczyk M, Feng P, Zhang J Molecules. 2025; 30(4).

PMID: 40005128 PMC: 11858480. DOI: 10.3390/molecules30040816.

Metformin's Effects on Cognitive Function from a Biovariance Perspective: A Narrative Review.

Chele D, Sirbu C, Mitrica M, Toma M, Vasiliu O, Sirbu A Int J Mol Sci. 2025; 26(4).

PMID: 40004246 PMC: 11855408. DOI: 10.3390/ijms26041783.

The intricate interplay between dietary habits and cognitive function: insights from the gut-brain axis.

Zhang R, Zhang M, Wang P Front Nutr. 2025; 12:1539355.

PMID: 39944956 PMC: 11813792. DOI: 10.3389/fnut.2025.1539355.

Metformin and Cognitive Performance in Patients With Type 2 Diabetes: An Umbrella Review.

Enderami A, Shariati B, Zarghami M, Aliasgharian A, Ghazaiean M, Darvishi-Khezri H Neuropsychopharmacol Rep. 2025; 45(1):e12528.

PMID: 39871536 PMC: 11772738. DOI: 10.1002/npr2.12528.

The oral-gut microbiota axis: a link in cardiometabolic diseases.

Xu Q, Wang W, Li Y, Cui J, Zhu M, Liu Y NPJ Biofilms Microbiomes. 2025; 11(1):11.

PMID: 39794340 PMC: 11723975. DOI: 10.1038/s41522-025-00646-5.

References

Evans L, Taylor J, Smith C, Pritchard H, Greenstein A, Allan S . Cardiovascular comorbidities, inflammation, and cerebral small vessel disease. Cardiovasc Res. 2021; 117(13):2575-2588. DOI: 10.1093/cvr/cvab284. View

Kong F, Hua Y, Zeng B, Ning R, Li Y, Zhao J . Gut microbiota signatures of longevity. Curr Biol. 2016; 26(18):R832-R833. DOI: 10.1016/j.cub.2016.08.015. View

Tucker G, Casey C, Phillips P, Connor H, Ward J, Woods H . Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981; 12(2):235-46. PMC: 1401849. DOI: 10.1111/j.1365-2125.1981.tb01206.x. View

Cani P, Neyrinck A, Fava F, Knauf C, Burcelin R, Tuohy K . Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007; 50(11):2374-83. DOI: 10.1007/s00125-007-0791-0. View

Vogt N, Kerby R, Dill-McFarland K, Harding S, Merluzzi A, Johnson S . Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017; 7(1):13537. PMC: 5648830. DOI: 10.1038/s41598-017-13601-y. View

Greer R, Dong X, Moraes A, Zielke R, Fernandes G, Peremyslova E . Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism. Nat Commun. 2016; 7:13329. PMC: 5114536. DOI: 10.1038/ncomms13329. View

Ticho A, Malhotra P, Dudeja P, Gill R, Alrefai W . Intestinal Absorption of Bile Acids in Health and Disease. Compr Physiol. 2019; 10(1):21-56. PMC: 7171925. DOI: 10.1002/cphy.c190007. View

Gupta A, Bisht B, Dey C . Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology. 2011; 60(6):910-20. DOI: 10.1016/j.neuropharm.2011.01.033. View

Jena P, Sheng L, Di Lucente J, Jin L, Maezawa I, Wan Y . Dysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticity. FASEB J. 2018; 32(5):2866-2877. PMC: 5901391. DOI: 10.1096/fj.201700984RR. View

10.

Lamichhane S, Sen P, Dickens A, Oresic M, Bertram H . Gut metabolome meets microbiome: A methodological perspective to understand the relationship between host and microbe. Methods. 2018; 149:3-12. DOI: 10.1016/j.ymeth.2018.04.029. View

11.

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

12.

Muriach M, Flores-Bellver M, Romero F, Barcia J . Diabetes and the brain: oxidative stress, inflammation, and autophagy. Oxid Med Cell Longev. 2014; 2014:102158. PMC: 4158559. DOI: 10.1155/2014/102158. View

13.

Cani P, de Vos W . Next-Generation Beneficial Microbes: The Case of . Front Microbiol. 2017; 8:1765. PMC: 5614963. DOI: 10.3389/fmicb.2017.01765. View

14.

El-Mir M, Detaille D, R-Villanueva G, Delgado-Esteban M, Guigas B, Attia S . Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci. 2007; 34(1):77-87. DOI: 10.1007/s12031-007-9002-1. View

15.

Zhang H, Sparks J, Karyala S, Settlage R, Luo X . Host adaptive immunity alters gut microbiota. ISME J. 2014; 9(3):770-81. PMC: 4331585. DOI: 10.1038/ismej.2014.165. View

16.

Napolitano A, Miller S, Nicholls A, Baker D, Van Horn S, Thomas E . Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014; 9(7):e100778. PMC: 4079657. DOI: 10.1371/journal.pone.0100778. View

17.

Lee C, Chae S, Jo S, Jerng U, Bae S . The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus. Int J Mol Sci. 2021; 22(7). PMC: 8037857. DOI: 10.3390/ijms22073566. View

18.

Chiang M, Cheng Y, Chen S, Yen C, Huang R . Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction. Exp Cell Res. 2016; 347(2):322-31. DOI: 10.1016/j.yexcr.2016.08.013. View

19.

Luong D, Oster R, Ashraf A . Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome. J Pediatr Endocrinol Metab. 2014; 28(5-6):649-55. DOI: 10.1515/jpem-2014-0201. View

20.

Lee Y, Kim A, Kim E, Lee S, Yu K, Jang I . Changes in the gut microbiome influence the hypoglycemic effect of metformin through the altered metabolism of branched-chain and nonessential amino acids. Diabetes Res Clin Pract. 2021; 178:108985. DOI: 10.1016/j.diabres.2021.108985. View